

Searching for a direct preparation of dihydropyrimidine-5-carboxamides under Biginelli reaction conditions

Irantzu Couto, Imanol Tellitu,* and Esther Domínguez

*Departamento de Química Orgánica II, Facultad de Ciencia y Tecnología,
Universidad del País Vasco – Euskal Herriko Unibertsitatea, 48940 Leioa (Bizkaia), Spain
E-mail: imanol.tellitu@ehu.es*

Dedicated to the memory of our colleague and friend Prof. Rafael Suau

Abstract

In this paper it is established a protocol leading to a series of dihydropyrimidine-5-carboxamides under Biginelli reaction conditions starting directly from 3-ketoamides as the 1,3-dicarbonyl component of the process. The best results have been found when chloroacetic acid is used as the catalyst under solvent free conditions.

Keywords: Multicomponent, Biginelli, dihydropyrimidines, heterocycles

Introduction

Organic chemists have found in the development of known and new multicomponent reactions (MCRs) an inspiration to quickly design straightforward entrances to large families of novel compounds, especially when these syntheses are coupled with combinatorial strategies.¹ Among them, the venerable 3-MCR Biginelli reaction has recently attracted a renewed interest based, primarily, on the discovery of many different catalysts that allow the preparation of the resultant dihydropyrimidines (DHPMs) with excellent results, as opposed to the limited success encountered in the original reports.² In addition, the finding of therapeutic and pharmacological properties³ as channel blockers, antihypertensive agents, α_{1a} antagonists and neuropeptide Y (NPY) antagonists, for example,⁴ explains the widespread presence of studies related to the “Biginelli compounds” in the specialized literature,⁵ not to mention the fact that several marine alkaloids, with interesting biological activities as well, include the DHPM motif in their structures.⁶ Apart from subtle modifications from the original design,⁷ the Biginelli reaction takes place by mixing an aldehyde (mainly aromatic aldehydes), substituted or unsubstituted urea (or thiourea), and an active 1,3-dicarbonyl compound under appropriate conditions,⁸ in combination with a selected catalyst (see Figure 1).




Figure 1

Most of the recent progress of this transformation is revealed from the large amount of publications showing the benefits of a number of different species that are able to catalyze the construction of the Biginelli adducts,⁹ a research that, in the vast majority of cases, has been developed using a 3-ketoester (Z=OR in Figure 1) as the active methylenic component of the reaction. In addition, post-transformations of the DHPM skeleton can be considered as an active field of research that has led to the preparation of a number of heterocycles of great interest. In particular, some of these structural alterations rely on the hydrolysis of the ester group followed by an amidation process to render 5-carboxamide substituted DHPMs (Z=NHR in Figure 1).¹⁰ On the other hand, it has to be mentioned that several examples of such type of derivatives have attracted the attention of medicinal chemists due to their well-recognized properties, examples of which are shown in Figure 2. Of special interest are the N3-acylated DHPMs, such as SNAP 6201 **1**, which are known to be excellent calcium channel modulator, as well as selective α_{1a} adrenergic receptor antagonists.^{3,5b} Similarly, DHPMs of type **2** have also shown good binding affinity (<1 nM) and excellent subtype selectivity for the α_{1a} adrenergic receptor.¹¹ In addition to the mitotic kinesin Eg5 inhibitor monastrol, screening of a library of related compounds in phenotype-based screens also led to the DHPM **3** which showed the colchicine-like property of destabilizing microtubules.¹² Finally, the preparation of **4**, which was found to have K_i values of 2.9, 537, and 1513 nM vs the α_{1a} , α_{1b} and α_{1d} receptors, respectively, has been also described.¹¹






Figure 2

Our own overview of the related literature has led to the conclusion that, in addition to the comparatively insignificant amount of reports including the construction of DHMP-5-carboxamides starting directly from 3-ketoamides,¹³ there is no account, to the best of our knowledge, in which a specific optimization protocol has been established for the one-step preparation of such kind of derivatives. Moreover, the resulting derivatives can be considered interesting starting points for future post-modifications. This paper shows our results in this area.

Results and Discussion

Selection of the catalyst

Initially, we explored the action of a series of catalysts with the aim of selecting the best protocol to ensure an efficient synthesis of a number of DHMP-5-carboxamides of type **8**. The catalysts under study were selected on the basis that (1) all of them had succeeded when applied to the same reaction employing 3-ketoesters, (2) they must be economically advantageous, (3) strongly acidic catalysts should be avoided to prevent undesired processes in highly functionalized substrates, and (4) the reaction and the work-up have to be as simple as possible. With these conditions, seven catalysts were selected and applied to our model reaction, exemplified in Scheme 1, that includes in all cases commercially available substrates. Thus, the reaction between acetoacetanilide **5a**, benzaldehyde **7a** and urea **6a** (molar rate 1:1:1.5) was set up in the presence of 10 mol% of a series of catalysts 1-7 in the indicated solvent (assays 1-4) or under solvent free conditions (assays 5-7) at the particular temperature.



cat. 1: CaF₂, EtOH, 40 °C, 8 h; **cat. 2:** SiCl₄, MeCN/DMF (2/1), rt, 72 h; **cat. 3:** SbCl₃, MeCN, reflux, 24 h; **cat. 4:** tartaric acid, MeOH, reflux, 18 h; **cat. 5:** ClCH₂COOH, 90 °C, 7 h; **cat. 6:** L-pro, rt, 18 h; **cat. 7:** Ce(NO₃)₃·6H₂O, 80 °C; **cat. 8:**¹⁴ AcOH, reflux; **cat. 9:**^{8b} AcOH/EtOH/ μ w, 120 °C; **cat. 10:**^{8b} AcOH/EtOH/Yb(OTf)₃, 120 °C; **cat. 11:**^{13c} Tungstophosphoric acid, 80 °C; **cat. 12:**¹⁵ AcOH/EtOH/CF₃SO₃H/YbCl₃, 120 °C.

Scheme 1. Experimental (cat 1-7) and reported values (cat 8-12) for DHMP **8a**.

The graphic (see Scheme 1) shows that the expected cyclization takes place in moderate to good yields in five out of the seven assays. The superior conditions (92% yield) were found when chloroacetic acid was used to assist the reaction, and slightly diminished results were obtained when catalysts 2, 3, 4 and 7 were employed. On the contrary, while the use of calcium fluoride resulted in a complex mixture of unidentified compounds, the use of L-proline did not promote the desired cyclization at all, and unreacted substrates were the only materials detected. The benefits from the use of chloroacetic acid over previously reported conditions are highlighted in the last portion of the graphic. Thus, previous reported syntheses of DHPM **8a** assisted by the use of catalysts 8-12 have shown diminished results except for catalyst 11, for which a comparable yield has been reported. However, tungstophosphoric acid (H₃PW₁₂O₄₀) is not commercially available and must be prepared.¹⁶ In addition, solvent-free reactions have many advantages and important aspects are reduced pollution, lower costs and the simplicity of the processes involved.¹⁷

Extension to the preparation of a series of DHMP-5-carboxamides (**8a-t**)

Once the best conditions have been established, a series of DHPM-5-carboxamides **8a-t** were prepared by heating, under solvent free conditions, mixtures of 3-ketoamides **5a-d**, substituted or unsubstituted ureas **6a-d**, and aromatic or aliphatic aldehydes **7a-i** in the presence of 10 mol% of chloroacetic acid for the required time (7-10 hours).




Table 1. Synthetic data for the series of DHPMs **8a-t** prepared. Yields for isolated compounds

R ¹	R ²	R ³	R ⁴	8 (%)	R ¹	R ²	R ³	R ⁴	8 (%)
Ph	H	H	Ph	8a (92)	H	Me	H	Ph	8k (73)
Ph	H	H	3-MeOC ₆ H ₄	8b (63)	Ph	Me	H	3-MeOC ₆ H ₄	8l (97)
Ph	H	H	2-thienyl	8c (89)	Ph	Me	Me	3-MeOC ₆ H ₄	8m (36)
Ph	H	H	4-NO ₂ C ₆ H ₄	8d (36)	Ph	Me	Me	Ph	8n (43)
Ph	Me	H	Ph	8e (75)	4-NO ₂ C ₆ H ₄	Me	Me	Ph	8o (42)
Ph	Me	H	3-HOC ₆ H ₄	8f (93)	Ph	Et	Et	3-MeOC ₆ H ₄	8p (21)
Ph	Me	H	2-BrC ₆ H ₄	8g (75)	2,4-Me ₂ C ₆ H ₃	Me	Me	Ph	8q (51)
Ph	Me	H	ⁱ Pr	8h (27)	H	Me	Me	Ph	8r (23)
Ph	Me	H	^t Bu	8i (47)	Ph	Me	Me	2-thienyl	8s (40)
H	H	H	Ph	8j (94)	Ph	Me	Me	2-NO ₂ C ₆ H ₄	8t (42)

The identity of the new heterocyclic compounds was established by spectroscopic means or by comparison with reported data. A clarifying piece of information comes from the ^1H NMR spectrum (CDCl_3) which reveals a singlet at ~ 5.5 ppm corresponding to H-4, a signal that confirms the construction of the DHPM skeleton. As expected, the same proton absorbs at higher field (~ 3.5 ppm) when aliphatic substituents are placed at C-4 position **8h,i**. Some other signals, especially N-H protons, experience clearly marked shifts when running the NMR spectra in different solvents. In particular, N(3)-H moves from ~ 5.5 ppm when the NMR is taken in CDCl_3 , to ~ 9 ppm when $\text{DMSO}-d_6$ was employed in order to improve the solubility of some of these derivatives. In view of the synthetic results summarized in Table 1, it can be firstly concluded that the reaction is clearly affected by two structural features: the substitution pattern of the urea component **6** and the nature of the aldehyde **7**. Thus, when unsubstituted and monosubstituted ureas **6a,b** were employed, the corresponding DHPM **8a-c,e-g,j-l** was obtained satisfactorily (63-93%) with non-activated, activated and heteroaromatic aldehydes, but disappointingly when starting from deactivated aldehydes (DHPM **8d**). It is known^{5a} that simple monosubstituted alkyl ureas generally react well, and in a regioselective manner, to provide good yield of N(1)-substituted DHPMs. Contrarily, and as previously reported, the use of N,N'-disubstituted ureas **6c,d** afforded heterocycles **8m-t** in a diminished yield in all cases (21-51%) regardless of the electronic nature of the aldehyde component **7** or the substitution of the 3-ketoamide **5**.¹⁸ The method under study seems to show also limitations with respect to the aliphatic nature of the aldehyde component. In both cases (DHPMs **8h,i**), either the iso-propyl or the tert-butyl substituted analogs were prepared in only moderate yields. Finally, it should be emphasized that all assays carried out with unsubstituted ketoamide **5b** pleasingly resulted once again in the formation of DHPMs **8j,k** in excellent yields.

Conclusions

The direct preparation of a series of DHPM-5-carboxamides by the Biginelli multicomponent reaction starting from acetylacetamides has been optimized with respect to the use of an adequate catalyst. This study has shown that the use of catalytic amounts of chloroacetic acid promotes the cyclocondensation reaction under solvent free conditions in most cases in good to excellent yields and with a superior behavior with respect to previously reported methods. The present direct approach avoids the hydrolysis/amidation steps that would be required to transform the most commonly employed 5-ethoxycarbonyl DHPM derivatives into the final 5-carboxamido-substituted dihydropyrimidines.

Experimental Section

General. All reagents were purchased and used as received. Melting points were measured using open glass capillaries. Infrared spectra were recorded as KBr as thin films and peaks are reported in cm^{-1} . Only representative absorptions are given. NMR spectra were taken in $\text{DMSO-}d_6$ on a Bruker AC-300 instrument at 20-25 °C. Chemical shifts (δ) were measured in ppm relative to solvent ($\delta=2.50$ for ^1H or 39.4 for ^{13}C) as internal standard. Coupling constants, J , are reported in hertz. DEPT experiments were used to assist with the assignment of the signals and structural determinations.

Typical procedure for the synthesis of DHPMs (8a-t)

A mixture of 3-ketoamide **5** (1 mmol), urea **6** (1.5 mmol), aldehyde **7** (1 mmol) and chloroacetic acid (10 mol %) was heated in an oil bath (90 °C) for 7-10 h in the absence of solvents. The progress of the reaction was monitored by TLC. When the reaction was completed, the flask was removed from the oil bath and allowed to stand at room temperature. Then, the mixture was poured into water and extracted with CH_2Cl_2 . The organic extracts were dried with Na_2SO_4 (anh), solvent was evaporated under reduced pressure, and the resultant residue was purified, if necessary, by column chromatography (Hexanes/EtOAc, 3/7) followed by crystallization from the appropriate solvent.

6-Methyl-2-oxo-*N*,4-diphenyl-1,2,3,4-tetrahydropyrimidin-5-carboxamide (8a). According to the general procedure DHPM **8a** was obtained from acetoacetanilide **5a**, benzaldehyde **7a** and urea **6a** in 92% yield as an orange pale solid: mp 236-240 °C (hexanes, lit.^{13c} 239-240).

4-(3-Methoxyphenyl)-6-methyl-2-oxo-*N*-phenyl-1,2,3,4-tetrahydropyrimidin-5-carboxamide (8b). According to the general procedure DHPM **8b** was obtained from acetoacetanilide **5a**, 3-methoxybenzaldehyde **7b** and urea **6a** in 63% yield. This material had to be purified by column chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 9/1) and triturated with hexanes to afford DHPM **8b** as a yellowish pure solid: mp 180-185 °C (hexanes); IR (film) ν 3237, 1672, 1400, 1200; ^1H NMR (300 MHz, $\text{DMSO-}d_6$) 2.02 (s, 3H), 3.67 (s, 3H), 5.37 (s, 1H), 6.52-6.80 (m, 4H), 6.82-6.99 (m, 3H), 7.20-7.23 (m, 3H), 8.33 (br s, 1H), 9.54 (br s, 1H); ^{13}C NMR (75 MHz, $\text{DMSO-}d_6$) 17.5, 55.4, 105.8, 112.7, 112.7, 118.8, 120.0, 123.5, 129.0, 130.0, 138.9, 139.7, 149.3, 153.1, 159.8, 165.8; HRMS calcd for $\text{C}_{19}\text{H}_{19}\text{N}_3\text{O}_3\cdot\text{H}^+$ 338.1517, found 338.1505.

6-Methyl-2-oxo-*N*-phenyl-4-(2-thienyl)-1,2,3,4-tetrahydropyrimidin-5-carboxamide (8c). According to the general procedure DHPM **8c** was obtained from acetoacetanilide **5a**, 2-thiophenecarboxaldehyde **7c** and urea **6a** in 89% yield as a yellowish solid: mp 174-178 °C (hexanes); IR (film) ν 3249, 1655, 1596; ^1H NMR (300 MHz, $\text{DMSO-}d_6$) 2.04 (s, 3H), 5.70 (s, 1H), 6.91-7.02 (m, 3H), 7.22-7.37 (m, 3H), 7.55-7.57 (m, 2H), 7.79 (br s, 1H), 8.85 (br s, 1H), 9.54 (br s, 1H); ^{13}C NMR (75 MHz, $\text{DMSO-}d_6$) 17.6, 51.0, 106.8, 120.2, 127.2, 129.0, 123.6, 124.0, 125.4, 139.7, 140.0, 149.2, 153.0, 165.4; HRMS calcd for $\text{C}_{16}\text{H}_{15}\text{N}_3\text{O}_2\text{S}\cdot\text{H}^+$ 314.0997, found 314.0963.

6-Methyl-4-(4-nitrophenyl)-2-oxo-N-phenyl-1,2,3,4-tetrahydropyrimidin-5-carboxamide

(8d). According to the general procedure DHPM **8d** was obtained from acetoacetanilide **5a**, 4-nitrobenzaldehyde **7d** and urea **6a** in 36% yield as a yellowish solid: mp 307-309 °C (hexanes, lit.¹⁹ 304-306); IR (film) ν 3364, 1720, 1518, 1533; ¹H NMR (300 MHz, DMSO-*d*₆) 2.04 (s, 3H), 5.48 (s, 1H), 6.96-7.01 (m, 1H), 7.20-7.25 (m, 2H), 7.50-7.53 (m, 3H), 7.73 (br s, 1H), 8.22 (d, *J*=8.7, 2H), 8.85 (br s, 1H), 9.60 (br s, 1H); ¹³C NMR (75 MHz, DMSO-*d*₆) 17.6, 55.2, 104.9, 120.1, 123.7, 124.3, 128.0, 129.0, 139.5, 139.8, 147.2, 151.9, 152.8, 165.5.

1,6-Dimethyl-2-oxo-N,4-diphenyl-1,2,3,4-tetrahydropyrimidin-5-carboxamide **(8e).**

According to the general procedure DHPM **8e** was obtained from acetoacetanilide **5a**, benzaldehyde **7a** and N-methylurea **6b** in 75% yield as a white solid: mp 216-222 °C (hexanes); IR (film) ν 3295, 1696, 1626, 1434; ¹H NMR (300 MHz, DMSO-*d*₆) 2.15 (s, 3H), 3.05 (s, 3H), 5.28 (s, 1H), 6.98-7.03 (m, 1H), 7.16-7.35 (m, 7H), 7.52-7.56 (m, 2H), 7.71 (br s, 1H), 9.80 (br s, 1H); ¹³C NMR (75 MHz, DMSO-*d*₆) 17.1, 29.8, 54.4, 109.9, 120.1, 123.7, 126.5, 127.8, 129.0, 139.5, 139.6, 144.1, 154.0, 166.3; HRMS calcd for C₁₉H₁₉N₃O₂·H⁺ 322.1556, found 322.1558.

4-(3-Hydroxyphenyl)-1,6-dimethyl-2-oxo-N-phenyl-1,2,3,4-tetrahydropyrimidin-5-carboxamide **(8f).**

According to the general procedure DHPM **8f** was obtained from acetoacetanilide **5a**, 3-hydroxybenzaldehyde **7e** and N-methylurea **6b** in 93% yield as a white solid: mp 238-242 °C (hexanes); IR (film) ν 3301, 1676, 1626, 1434; ¹H NMR (300 MHz, DMSO-*d*₆) 2.12 (s, 3H), 3.06 (s, 3H), 5.20 (s, 1H), 6.55-6.67 (m, 3H), 6.96-7.08 (m, 2H), 7.21-7.28 (m, 2H), 7.55-7.59 (m, 2H), 7.65 (br s, 1H), 9.37 (s, 1H), 9.78 (s, 1H); ¹³C NMR (75 MHz, DMSO-*d*₆) 17.1, 29.8, 54.3, 110.1, 113.3, 114.77, 116.9, 120.1, 123.7, 129.0, 129.9, 139.3, 139.7, 145.7, 154.1, 158.0, 166.4.

4-(2-Bromophenyl)-1,6-dimethyl-2-oxo-N-phenyl-1,2,3,4-tetrahydropyrimidin-5-carboxamide **(8g).**

According to the general procedure DHPM **8g** was obtained from acetoacetanilide **5a**, 2-bromobenzaldehyde **7f** and N-methylurea **6b** in 75% yield as a white solid: mp 201-204 °C (hexanes); IR (film) ν 3211, 1693, 1627; ¹H NMR (300 MHz, DMSO-*d*₆) 2.13 (s, 3H), 3.10 (s, 3H), 5.64 (s, 1H), 6.95-7.02 (m, 1H), 7.15-7.54 (m, 8H), 7.61 (s, 1H), 9.89 (s, 1H); ¹³C NMR (75 MHz, DMSO-*d*₆) 17.1, 29.8, 54.6, 109.0, 120.0, 120.1, 122.2, 123.7, 128.8, 129.0, 130.1, 133.1, 139.3, 139.5, 142.7, 153.4, 165.8; HRMS calcd for C₁₉H₁₈⁷⁹BrN₃O₂·H⁺ 400.0668, found 400.0661.

1,6-Dimethyl-4-isopropyl-2-oxo-N-phenyl-1,2,3,4-tetrahydropyrimidin-5-carboxamide **(8h).**

According to the general procedure DHPM **8h** was obtained from acetoacetanilide **5a**, isobutyraldehyde **7g** and N-methylurea **6b** in 27% yield. This material had to be purified by column chromatography (EtOAc/hexanes, 3/7) and triturated in hexanes to afford DHPM **8h** as a white pure solid: mp 239-241 °C (hexanes); IR (film) ν 3305, 1692, 1653; ¹H NMR (300 MHz, DMSO-*d*₆) 0.77-0.83 (m, 6H), 1.52-1.62 (m, 1H), 2.07 (s, 3H), 2.93 (s, 3H), 3.96 (s, 1H), 7.02-7.04 (m, 1H), 7.20-7.32 (m, 3H), 7.57-7.64 (m, 2H), 9.78 (s, 1H); ¹³C NMR (75 MHz, DMSO-*d*₆) 16.9, 17.0, 18.2, 29.7, 35.0, 56.1, 109.3, 120.9, 123.7, 129.0, 139.5, 139.8, 154.7, 167.3; HRMS calcd for C₁₆H₂₁N₃O₂·H⁺ 288.1723, found 288.1712.

4-tert-Butyl-1,6-dimethyl-2-oxo-N-phenyl-1,2,3,4-tetrahydropyrimidin-5-carboxamide (8i). According to the general procedure DHPM **8h** was obtained from acetoacetanilide **5a**, pivalaldehyde **7h** and N-methylurea **6b** in 47% yield. This material had to be purified by column chromatography (EtOAc/hexanes, 9/1) and triturated in hexanes to afford DHPM **8i** as a white pure solid: mp 259-262 °C (hexanes); IR (film) ν 3290, 1675, 1653; ^1H NMR (300 MHz, DMSO- d_6) 0.80 (s, 9H), 2.09 (s, 3H), 2.96 (s, 3H), 3.83 (s, 1H), 7.01-7.04 (m, 1H), 7.24-7.30 (m, 3H), 7.57-7.60 (m, 2H), 9.78 (s, 1H); ^{13}C NMR (75 MHz, DMSO- d_6) 16.8, 25.4, 29.7, 38.7, 59.5, 109.3, 120.1, 123.6, 129.0, 139.8, 140.2, 155.1, 168.1; HRMS calcd for $\text{C}_{17}\text{H}_{23}\text{N}_3\text{O}_2\cdot\text{H}^+$ 302.1873, found 302.1869.

6-Methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidin-5-carboxamide (8j). According to the general procedure DHPM **8j** was obtained from acetoacetamide **5b**, benzaldehyde **7a** and urea **6a** in 94% yield as a white solid: mp 218-224 °C (hexanes); ^1H NMR (300 MHz, DMSO- d_6) 2.04 (s, 3H), 5.21 (s, 1H), 6.82 (br s, 2H), 7.20-7.34 (m, 5H), 7.42-7.51 (s, 1H), 8.54 (s, 1H); ^{13}C NMR (75 MHz, DMSO- d_6) 17.6, 55.1, 104.9, 126.9, 127.6, 128.8, 139.3, 144.9, 153.2, 168.6; HRMS calcd for $\text{C}_{12}\text{H}_{13}\text{N}_3\text{O}_2\cdot\text{H}^+$ 232.1086, found 232.1093.

1,6-Dimethyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidin-5-carboxamide (8k). According to the general procedure DHPM **8k** was obtained from acetoacetamide **5b**, benzaldehyde **7a** and N-methylurea **6b** in 73% yield as a white solid: mp 252-259 °C (hexanes); IR (film) ν 3375, 1690, 1654, 1396; ^1H NMR (300 MHz, DMSO- d_6): 2.18 (s, 3H), 3.01 (s, 3H) 5.15 (s, 1H), 6.96 (br s, 2H), 7.20-7.32 (m, 5H), 7.64 (s, 1H); ^{13}C NMR (75 MHz, DMSO- d_6) 16.8, 29.8, 54.0, 109.2, 126.6, 127.7, 128.8, 139.9, 144.2, 154.1, 169.2; HRMS calcd for $\text{C}_{13}\text{H}_{15}\text{N}_3\text{O}_2\cdot\text{H}^+$ 246.1243, found 246.1240.

4-(3-Methoxyphenyl)-1,6-dimethyl-2-oxo-N-phenyl-1,2,3,4-tetrahydropyrimidin-5-carboxamide (8l). According to the typical procedure DHPM **8l** was obtained from acetoacetanilide **5a**, 3-methoxybenzaldehyde **7b** and N-methylurea **6b** in 97% yield as a pale brown solid after triturating of the residue from hexanes: mp 148-152 °C (hexanes); IR (film) ν 3290, 1655, 1488; ^1H NMR (300 MHz, CDCl_3) 2.29 (s, 3H), 3.23 (s, 3H), 3.77 (s, 3H), 5.30 (s, 1H), 6.55-7.25 (m, 11H); ^{13}C NMR (75 MHz, CDCl_3) 16.7, 29.9, 55.2, 55.6, 109.0, 112.1, 113.8, 118.4, 119.9, 124.4, 128.9, 130.4, 137.7, 140.2, 143.9, 153.8, 160.3, 165.7; MS $[\text{M}+1]$ m/z : 352 (100), 309 (32), 259 (79), 233 (31), 122 (35), 94 (56); HRMS calcd for $\text{C}_{20}\text{H}_{21}\text{N}_3\text{O}_3\cdot\text{H}^+$: 352.1661, found: 352.1670.

4-(3-Methoxyphenyl)-1,3,6-trimethyl-2-oxo-N-phenyl-1,2,3,4-tetrahydropyrimidin-5-carboxamide (8m). According to the typical procedure DHPM **8m** was obtained from acetoacetanilide **5a**, 3-methoxybenzaldehyde **7b** and N,N'-dimethylurea **5c** in 36% yield as a pale brown solid after purification by column chromatography (Hexanes/EtOAc, 3/7) followed by crystallization from hexanes: mp 66-68 °C (hexanes); IR (film) ν 3290, 1648, 1532; ^1H NMR (300 MHz, CDCl_3) 2.22 (s, 3H), 2.88 (s, 3H), 3.21 (s, 3H), 3.71 (s, 3H), 5.08 (s, 1H), 6.78-6.80 (m, 3H), 7.00-7.09 (m, 2H), 7.21-7.33 (m, 5H); ^{13}C NMR (75 MHz, CDCl_3) 16.6, 30.1, 33.9, 55.2, 62.3, 108.7, 112.4, 113.3, 118.7, 119.8, 124.4, 129.9, 130.4, 137.7, 140.0, 141.8, 153.7,

160.3, 165.7; MS [M+1] m/z : 366 (64), 350 (30), 309 (79), 233 (30), 273 (100); HRMS calcd for $C_{21}H_{23}N_3O_3 \cdot H^+$: 366.1827, found: 366.1818.

1,3,6-Trimethyl-2-oxo-*N*,4-diphenyl-1,2,3,4-tetrahydropyrimidin-5-carboxamide (8n).

According to the typical procedure DHPM **8n** was obtained from acetoacetanilide **5a**, benzaldehyde **7a** and *N,N'*-dimethylurea **6c** in 43% yield as a yellowish oil after purification by column chromatography (Hexanes/EtOAc, 3/7): IR (film) ν 3295, 1654, 1540; 1H NMR (300 MHz, $CDCl_3$) 2.22 (s, 3H), 2.88 (s, 3H), 3.21 (s, 3H), 5.10 (s, 1H), 6.80-6.91 (br s, 1H), 7.00-7.41 (m, 10H); ^{13}C NMR (75 MHz, $CDCl_3$) 16.7, 30.6, 34.2, 62.4, 108.9, 119.9, 124.4, 124.6, 126.5, 128.7, 129.0, 129.5, 137.7, 140.0, 140.2, 153.7, 165.7; MS [M+1] m/z : 336 (73), 335 (33), 320 (32), 243 (100); HRMS calcd for $C_{20}H_{21}N_3O_2 \cdot H^+$: 336.1712, found: 336.1707.

***N*-(*p*-Nitrophenyl)-1,3,6-trimethyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidin-5-**

carboxamide (8o). According to the typical procedure DHPM **8o** was obtained from *N-p*-nitrophenylacetoacetamide **5c**, benzaldehyde **7a** and *N,N'*-dimethylurea **6c** in 42% yield as a yellowish solid after purification by column chromatography (Hexanes/EtOAc, 3/7) followed by crystallization from hexanes: mp 224-228 °C (hexanes); IR (film) ν 3266, 1646, 1501; 1H NMR (300 MHz, $CDCl_3$) 2.31 (s, 3H), 2.88 (s, 3H), 3.28 (s, 3H), 5.07 (s, 1H), 7.24-7.31 (m, 3H), 7.35-7.41 (m, 2H), 7.46-7.53 (m, 2H), 7.58-7.62 (br s, 1H), 8.10-8.16 (m, 2H); ^{13}C NMR (75 MHz, $CDCl_3$) 30.7, 34.8, 60.5, 64.6, 98.9, 126.4, 128.6, 128.7, 129.0, 130.9, 137.4, 137.8, 138.9, 151.9, 158.1, 169.6; (Compound **6e** resulted to be unstable under all conditions employed to register its MS/HR mass spectrum).

1,3-Diethyl-4-(3-methoxyphenyl)-6-methyl-2-oxo-*N*-phenyl-1,2,3,4-tetrahydropyrimidin-5-

carboxamide (8p). According to the typical procedure DHPM **8p** was obtained from acetoacetanilide **5a**, 3-methoxybenzaldehyde **7b** and *N,N'*-diethylurea **6d** in 21% yield as a pale brown solid after purification by column chromatography (Hexanes/EtOAc, 3/7) followed by crystallization from hexanes: mp 64-70 °C (hexanes); IR (film) ν 2916, 1668, 1596; 1H NMR (300 MHz, $CDCl_3$) 1.00-1.14 (m, 3H), 1.19-1.26 (m, 3H), 2.23-2.37 (m, 1H), 2.88-2.94 (m, 1H), 3.63-3.70 (m, 1H), 3.74 (s, 3H), 3.94 (m, 1H), 5.12 (s, 1H), 6.83-6.92 (m, 4H), 7.02-7.14 (m, 1H), 7.22-7.32 (m, 5H); ^{13}C NMR (75 MHz, $CDCl_3$) 12.7, 15.2, 16.2, 38.0, 41.3, 55.3, 59.9, 100.0, 109.1, 112.2, 114.0, 119.0, 124.4, 129.1, 130.3, 137.6, 139.3, 143.3, 152.6, 160.4, 166.0; MS [M+1] m/z : 394 (100), 393 (31), 378 (33), 323 (40), 301 (71); HRMS calcd for $C_{23}H_{27}N_3O_3 \cdot H^+$: 394.2130, found: 394.2115.

***N*-(2,4-dimethylphenyl)-4-phenyl-1,3,6-trimethyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-**

carboxamide (8q). According to the typical procedure DHPM **8q** was obtained from *N*-(2,4-dimethylphenyl)acetoacetamide **5d**, 3-methoxybenzaldehyde **7b** and *N,N'*-dimethylurea **6c** in 51% yield as a yellowish solid after purification by column chromatography (Hexanes/EtOAc, 3/7) followed by crystallization from hexanes: mp 185-190 °C (hexanes); IR (film) ν 3261, 1655, 1515; 1H NMR (300 MHz, $CDCl_3$) 1.78 (s, 3H), 2.31 (s, 3H), 2.34 (s, 3H), 2.87 (s, 3H), 3.23 (s, 3H), 5.07 (s, 1H), 6.49-6.56 (m, 1H), 6.83-7.00 (m, 2H), 7.20-7.41 (m, 5H), 7.46-7.53 (m, 1H); ^{13}C NMR (75 MHz, $CDCl_3$) 16.7, 17.3, 20.8, 30.5, 34.1, 62.4, 108.6, 123.3, 126.7,

127.1, 128.5, 129.3, 129.5, 131.0, 133.3, 135.0, 139.7, 139.9, 153.7, 166.0; MS [M+1] *m/z*: 364 (100), 363 (42), 243 (61); HRMS calcd for C₂₂H₂₅N₃O₂·H⁺: 364.2025, found: 364.2027.

1,3,6-Trimethyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidin-5-carboxamide (8r). According to the typical procedure DHPM **8r** was obtained from acetoacetamide **5b**, benzaldehyde **7a** and N,N'-dimethylurea **6c** in 23% yield as a yellowish solid after purification by column chromatography (Hexanes/EtOAc, 3/7) followed by crystallization from hexanes: mp 204-208 °C (hexanes); IR (film) ν 3197, 1646, 1601; ¹H NMR (300 MHz, CDCl₃) 2.29 (s, 3H), 2.86 (s, 3H), 3.20 (s, 3H), 5.04 (s, 1H), 5.36-5.57 (br s, 2H), 7.20-7.32 (m, 5H); ¹³C NMR (75 MHz, CDCl₃) 16.7, 30.7, 34.2, 62.7, 107.3, 126.6, 128.5, 129.2, 139.9, 141.4, 153.7, 169.4; MS [M+1] *m/z*: 260 (91), 244 (100), 242 (96), 378 (33), 203 (64), 182 (59), 164 (55); HRMS calcd for C₁₄H₁₇N₃O₂·H⁺: 260.1399, found: 260.1406.

1,3,6-Trimethyl-4-(2-thienyl)-2-oxo-N-phenyl-1,2,3,4-tetrahydropyrimidin-5-carboxamide (8s). According to the typical procedure DHPM **8s** was obtained from acetoacetanilide **5a**, 2-thienylcarboxaldehyde **7c** and N,N'-dimethylurea **6b** in 40% yield as a pale brown solid after purification by column chromatography (Hexanes/EtOAc, 1/1) followed by crystallization from hexanes: mp 137-140 °C (hexanes); IR (film) ν 3285, 1653, 1438; ¹H NMR (300 MHz, CDCl₃) 2.35 (s, 3H), 2.97 (s, 3H), 3.25 (s, 3H), 5.33 (s, 1H), 6.97-7.10 (m, 3H), 7.26-7.36 (m, 6H); ¹³C NMR (75 MHz, CDCl₃) 16.4, 30.6, 34.2, 57.4, 108.2, 119.8, 124.3, 125.9, 126.5, 127.1, 129.0, 137.7, 142.4, 143.1, 153.7, 169.4; MS [M+1] *m/z*: 342 (100), 341 (45), 285 (34), 258 (65), 249 (100); HRMS calcd for C₁₈H₁₉N₃O₂S·H⁺: 342.1276, found: 342.1282.

1,3,6-Trimethyl-4-(o-nitrophenyl)-2-oxo-N-phenyl-1,2,3,4-tetrahydropyrimidin-5-carboxamide (8t). According to the typical procedure DHPM **8t** was obtained from acetoacetanilide **5a**, 2-nitrobenzaldehyde **7i** and N,N'-dimethylurea **6c** in 42% yield as a pale brown solid after purification by column chromatography (Hexanes/EtOAc, 2/8) followed by crystallization from hexanes: mp 236-239 °C (hexanes); IR (film) ν 3285, 1653, 1437; ¹H NMR (300 MHz, CDCl₃) 2.40 (s, 3H), 2.84 (s, 3H), 3.29 (s, 3H), 6.04 (s, 1H), 7.03-7.12 (m, 1H), 7.23-7.30 (m, 3H), 7.37-7.68 (m, 5H), 7.74-7.84 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) 17.1, 30.8, 33.9, 56.3, 106.3, 120.2, 124.3, 124.5, 128.9, 129.5, 129.6, 134.1, 134.6, 137.6, 143.1, 153.0, 164.0, 176.2; MS [M+1] *m/z*: 381 (100), 363 (36), 349 (33), 228 (40), 301 (65); HRMS calcd for C₂₀H₂₀N₄O₄·H⁺: 381.1563, found: 381.1565.

Supporting Information

Copies of NMR spectra for compounds **8a-t** are included.

Acknowledgements

Financial support from the Basque Government (GIU 06/87), and the Spanish Ministry of Science and Innovation CTQ2007-64501/BQU) is gratefully acknowledged. The authors gratefully acknowledge PETRONOR, S. A. (Muskiz, Bizkaia) for the generous gift of hexanes. I. C. thanks also the Spanish Ministry for a grant.

References and Notes

1. (a) Ganem, B. *Acc. Chem. Res.* **2009**, *42*, 463. (b) Armstrong, R. W.; Combs, A. P.; Tempest, P. A.; Brown, S. D.; Keating, T. A. *Acc. Chem. Res.* **1996**, *29*, 123.
2. Biginelli, P. *Gazz. Chim. Ital.* **1893**, *23*, 360.
3. Kappe, C. O. *Eur. J. Med. Chem.* **2000**, *35*, 1043.
4. (a) Atwal, K. S.; Rovnyak, G. C.; Kimball, S. D.; Floyd, D. M.; Moreland, S.; Swanson, B. N.; Gougoutas, J. Z.; Schwartz, J.; Smillie, K. M.; Malley, M. F. *J. Med. Chem.*, **1990**, *33*, 2629. (b) Rovnyak, G. C.; Kimball, S. D.; Beyer, B.; Cucinotta, G.; DiMarco, J. D.; Gougoutas, J. Z.; Hedberg, A.; Malley, M. F.; McCarthy, J. P.; Zhang, R.; Moreland, S. *J. Med. Chem.* **1995**, *38*, 119, and references cited therein.
5. (a) Kappe, C. O. *Org. React.* **2004**, *63*, 1. (b) C. O. Kappe, *Acc. Chem. Res.* **2000**, *33*, 879. (c) Kappe, C. O. *Tetrahedron* **1993**, *49*, 6937.
6. See, for example: Overman, L. E.; Rabinowitz, M. H.; Renhowe, P. A. *J. Am. Chem. Soc.* **1995**, *117*, 2657.
7. The "Atwal modification" takes place between a preformed enone and a protected urea or thiourea. See, for example: (a) O'Reilly, B. C.; Atwal, K. S. *Heterocycles* **1987**, *26*, 1185. (b) Atwal, K. S.; O'Reilly, B. C.; Gougoutas, J. Z.; Malley, M. F. *Heterocycles* **1987**, *26*, 1189. (c) For a stepwise strategy based on the Mannich reaction of 3-ketoesters and acylimines, see: Goss, J. M.; Scahus, S. E. *J. Org. Chem.* **2008**, *73*, 7651.
8. The original conditions described by Biginelli required the use of HCl activation in refluxing ethanol, but more sophisticated recent protocols have been described. (a) For soluble polymer-supported synthesis, see: Wang, Y. G.; Xia, M. *Tetrahedron Lett.* **2002**, *43*, 7703. (b) For solvent-free microwave-irradiated conditions, see: Stadler, A.; Kappe, C. O. *J. Comb. Chem.* **2001**, *3*, 624. (c) The preparation of Biginelli compounds under sonochemical activation has been described in: Zhidovinova, M. S.; Fedorova, O. V.; Rusinov, G. L.; Ovchinnikova, I. G. *Mol. Divers.* **2003**, *6*, 323. (d) The Biginelli condensation takes place as well in ionic liquids. See, for example: Peng, J.; Deng, Y. *Tetrahedron Lett.* **2001**, *42*, 5917.
9. Many of the improved protocols involve the use of Lewis acids instead of the traditional mineral acid catalysts. For a recent review, see: Vdovina, S. V.; Mamedov, V. A. *Russ. Chem. Rev.* **2008**, *77*, 1017 and references cited therein.

10. (a) Klein, E.; DeBonis, S.; Thiede, B.; Skoufias, D.; Kozielski, F.; Lebeau, L. *Bioorg. Med. Chem.* **2007**, *15*, 6474. (b) Desai, B.; Dallinger, D.; Kappe, C. O. *Tetrahedron* **2006**, *62*, 4651. (c) Desai, B.; Kappe, C. O. *J. Comb. Chem.* **2005**, *7*, 641.
11. Barrow, J. C.; Nantermet, P. G.; Selnick, H. G.; Glass, K. L.; Rittle, K. E.; Gilbert, K. F.; Steele, T. G.; Homnick, C. F.; Freidinger, R. M.; Ransom, R. W.; Kling, P.; Reiss, D.; Broten, T. P.; Schorn, T. W.; Chang, R. S. L.; O'Malley, S. S.; Olah, T.; Ellis, J. D.; Barrish, A.; Kassahun, K.; Leppert, P.; Nagarathnam, D.; Forray, C. *J. Med. Chem.* **2000**, *43*, 2703.
12. Haggarty, S. J.; Mayer, T. U.; Miyamoto, D. T.; Fathi, R.; King, R. W.; Mitchison, T. J.; Schreiber, S. L. *Chem. Biol.* **2000**, *7*, 275.
13. (a) Pansuriya, A. M.; Savant, M. M.; Bhuvu, C. V.; Singh, J.; Naliapara, Y. T. *Arkivoc* **2009**, (vii), 70. (b) Schmidt, R. J.; Lombardo, L. J.; Traeger, S. C.; Williams, D. K. *Tetrahedron Lett.* **2008**, *49*, 3009. (c) Amini, M. M.; Shaabani, A.; Bazgir, A. *Catal. Commun.* **2006**, *7*, 843. (d) Chevanov, V. A.; Muravyova, E. A.; Desenko, S. M.; Mustov, V. I.; Knyazeva, I. V.; Shishkina, S. V.; Shishkin, O. V.; Kappe, C. O. *J. Comb. Chem.* **2006**, *8*, 427.
14. Duburs, G.; Khanina, E. L. *Khim. Geterotsikl. Soedin.* **1976**, 220; *Chem. Abstr.* **1976**, *85*, 32946.
15. Kappe, C. O.; Stadler, A. *Methods in Enzymology* **2003**, 369 (Part B), 197.
16. Kozhevnikov, I. V. in *Catalysis for Fine Chemical Synthesis; Catalysis by Polyoxometalates*, Roberts, S. M.; Kozhevnikov, I. V. and Derouane, E. (Series Eds.), Wiley: New York, 2002; Vol. 2, pp 216.
17. (a) Tanaka, K.; Toda, F. *Chem. Rev.* **2000**, *100*, 1025. (b) Cave, G. W. V.; Raston, C. L.; Scott, J. L. *Chem. Commun.* **2001**, 2159. (c) Metzger, J. O. In *Organic Synthesis Highlights V*; Schmalz, H. -G., Wirth, T., Eds.; Wiley-VCH: Weinheim, 2003; p 82. (d) Martins, M. A. P.; Frizzo, C. P.; Moreira, D. N.; Buriol, L.; Machado, P. *Chem. Rev.* **2009**, *109*, 4140.
18. Literature shows examples directed to circumvent this problem. Singh, K.; Arora, D.; Singh, S. *Tetrahedron Lett.* **2006**, *47*, 4205. In our hands, the application of the reported conditions was not successful at all.
19. Previously prepared in: Virsodia, V.; Pissurlenkar, R. R. S.; Manvar, D.; Dholakia, C.; Adlakha, P.; Shah, A.; Coutinho, E. C. *Eur. J. Med. Chem.* **2008**, *43*, 2103.